Cardiothoracic & vascular anesthesia
Methylprednisolone and Endothelial Dysfunction in Cardiac Surgery: A Pilot Randomized Trial
Primary result · Maximal post-CPB FMDResult — go to the resultDifference 0.60 95% CI −1.5 to 2.7Authors' conclusion
Methylprednisolone did not significantly affect CPB-associated endothelial dysfunction markers in elective cardiac surgery patients.
Study context
- Population
- Patients scheduled for elective cardiac surgery with cardiopulmonary bypass (CPB)
- Participants
- 20 vs 20
- Comparison
- IV methylprednisolone vs placebo at anaesthesia induction
- Methylprednisolonen = 20
- Placebon = 20reference
- Primary endpoint
- Endothelial dysfunction, assessed by flow-mediated dilation (FMD) during a vascular occlusion test (maximal post-CPB FMD)
Methodological detailspilot, parallel-group, placebo-controlled, single-centre
- Pilot
- Parallel-group
- Placebo-controlled
- Single-centre
Primary result
Maximal post-CPB FMD
Difference
0.60
95% CI −1.5 to 2.7
P = 0.57
By group
Methylprednisolone vs Placebo
difference 0.60 (95% CI −1.5 to 2.7); P = 0.57
As reported in the abstract
Secondary outcomes
Median
| Outcome | Methylprednisolone | Placebo | Difference (95% CI) | P value | |
|---|---|---|---|---|---|
| FMD · POD 1 | 6.9% (IQR 3.6%–9.8%) | 8.1% (IQR 4.3%–11.6%) | −1.0 (−3.6 to 1.6) | P = 0.46 | |
| −4−202Difference (linear scale) |
Other measurements (NIRS StO2 reperfusion slope, syndecan-1, variations over time)
- No other significant differences between groups
Correlation between severity of flow-mediated dilation (FMD) alteration and syndecan-1 levels
- Significant correlation (r = 0.21, p = 0.03)
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Methylprednisolone and Endothelial Dysfunction in Cardiac Surgery: A Pilot Randomized Trial. Acta Anaesthesiol Scand. Published August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →